Immunohistochemical expression of SOX2 and OCT4 in primary odontogenic keratocyst, recurrent odontogenic keratocyst, and odontogenic keratocyst treated by the decompression technique

原发性牙源性角化囊肿、复发性牙源性角化囊肿以及经减压术治疗的牙源性角化囊肿中SOX2和OCT4的免疫组织化学表达

阅读:1

Abstract

INTRODUCTION: Odontogenic keratocyst (OKC) is a developmental odontogenic cyst with distinct pathological features and a high recurrence rate. Interest among OKCs became apparent by the clinical challenges associated with their treatment. Pathogenesis of OKCs is a multifactorial process, which is linked to several signalling pathways and expression of stem cell markers such as SOX2 and OCT4. MATERIALS AND METHODS: Thirty cases of OKCs were categorised into three groups: primary (n = 10), recurrent (n = 10), and decompressed (n = 10). Tissue sections were immunohistochemically stained using anti-SOX2 and anti-OCT4 antibodies. Staining distribution, intensity, and localisation were evaluated qualitatively. Quantitative assessment was performed using Image Pro Plus software, and statistical analysis was conducted using SPSS software and results were statistically analysed. RESULTS: SOX2 expression was observed in 80% of primary, 80% recurrent, and 90% of decompressed OKCs, with significant differences in staining intensity (P = 0.032). Most cases exhibited diffuse, nuclear, and cytoplasmic positivity across the full epithelial thickness, particularly in suprabasal layers. OCT4 expression was limited to 10% of primary and 20% of recurrent OKCs, with no positivity observed in decompressed cases. OCT4 did not show statistically significant differences. Remmele scores for both markers were not statistically significant across the groups. CONCLUSION: High expression of SOX2 in OKCs supports its role as a marker of epithelial stemness and a potential biomarker for aggressive behaviour and recurrence. Limited expression of OCT4 suggests a minimal role in OKC pathobiology, possibly associated with early differentiation. Lack of OCT4 expression in decompressed lesions raises questions about the molecular efficacy of decompression therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。